Related Experiment Video
Updated: Jul 13, 2026
06:28
E-Patient Counseling Trial (E-PACO): Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
Published on: August 1, 2019
Can an educational program optimize PDE5i therapy? A study of Canadian primary care practices
Gerald Brock1, Serge Carrier, Richard Casey
1Department of Urology, St. Joseph's Healthcare, London, Ontario, Canada.
The Journal of Sexual Medicine
|July 20, 2007
Summary
A new educational program for erectile dysfunction (ED) patients using sildenafil did not significantly improve treatment satisfaction scores compared to usual care. However, patients and physicians found the educational materials valuable.
Area of Science:
- Urology
- Primary Care Medicine
- Health Education
Background:
- Optimizing therapy with phosphodiesterase type 5 inhibitors is crucial for erectile dysfunction (ED) treatment.
- Patient instructions play a key role in enhancing treatment efficacy.
Purpose of the Study:
- To evaluate the impact of an educational program (Treatment Optimization Program - TOP) for new sildenafil users.
- To compare the TOP tool against usual ED management in Canadian primary care.
Main Methods:
- A multicenter, 6-month cluster randomized prospective study involving 2,573 men naive to sildenafil.
- Sites were randomized to receive the TOP tool (brochure, video) or usual care.
- Treatment satisfaction assessed using the Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) at 3 and 6 months.
Main Results:
- High overall treatment satisfaction with sildenafil (9/10 patients).
- No significant difference in EDITS scores between the TOP and non-TOP groups.
- High patient satisfaction with TOP materials (video, brochure) and physician willingness to use the tool (84%).
Conclusions:
- The Treatment Optimization Program (TOP) is a valuable tool for managing newly diagnosed ED patients.
- TOP offers time-efficient benefits for both patients and physicians in ED management.
- While not improving EDITS scores, the educational components were well-received.
Related Concept Videos
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:28Dosage Regimens: Designs and Approaches
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...